CURE’s mesothelioma page is a go-to resource for oncology news and updates in the world of mesothelioma Here, readers will find cancer articles, videos, podcasts, and more with expert insight to the latest treatments and research in mesothelioma.
November 3rd 2022, 5:00pm
After being diagnosed with mesothelioma, I learned to advocate for myself, and realized that it was an incredibly important life skill to have.
October 3rd 2022, 5:00pm
I grew up in a society where mental health was stigmatized, but cancer made me realize that it helps to speak up about these issues.
August 26th 2022, 6:00pm
After being homebound for two years from the COVID-19 pandemic, I was eager to get out, though I did have many cancer/COVID-19 concerns.
August 24th 2022, 1:00pm
Patients with malignant pleural mesothelioma tended to have prolonged benefit when treated with Keytruda plus Lenvima in the PEMMELA clinical trial.
July 29th 2022, 5:00pm
I don’t fit the profile of someone who gets diagnosed with mesothelioma, so my diagnosis came as a shock.
June 28th 2022, 3:00pm
The FDA plans to accelerate its review of IK-930, an investigational drug, for the treatment of patients with unresectable NF2-deficient malignant pleural mesothelioma, a rare cancer.
November 26th 2021, 10:00pm
Part B of the DIONE-01 study will look at whether IOA-244 increases anti-tumor responses in expansion groups of patients.
November 16th 2021, 10:00pm
Imfinzi plus platinum-pemetrexed chemotherapy induced survival improvements in patients with previously untreated, unresectable malignant pleural mesothelioma, compared with chemotherapy alone.
October 26th 2021, 3:00pm
Treatment with the immunotherapy Opdivo for relapsed, malignant mesothelioma may represent a useful choice for patients with minimal therapy options.
September 20th 2021, 3:00pm
The average survival for patients with malignant pleural mesothelioma was less than a month after being diagnosed with COVID-19, according to a small study.
Radiotherapy and EGFR-TKIs May Improve Treatment Outcomes in Lung Cancer
FDA Approves Ziihera for Some With Biliary Tract Cancer
PD-L1, KIM-1 Levels May Predict Kidney Cancer Response to Opdivo, Yervoy
Donor Lymphocyte Infusion May Improve Survival in R/R MDS